Email ID
Password
Scrip   
US panel says toxicities of J&J's Yondelis outweigh benefits
16 July 2009
Sue Sutter

Centocor Ortho Biotech's ( Johnson & Johnson) Yondelis (trabectedin) lacks a favourable risk/benefit profile to support use in relapsed ovarian cancer, the US FDA's oncologic drugs advisory committee said in a 14 to one vote.

The panellists agreed that trabectedin, when used in...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36